Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s share price was down 4.3% during mid-day trading on Monday . The company traded as low as $13.40 and last traded at $13.40. Approximately 18,231 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 195,778 shares. The stock had previously closed at $14.00.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on TYRA shares. Oppenheimer lifted their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. HC Wainwright cut their target price on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, November 11th. Wedbush reiterated an "outperform" rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of "Buy" and a consensus target price of $31.00.
Check Out Our Latest Stock Analysis on Tyra Biosciences
Tyra Biosciences Price Performance
The firm has a market cap of $721.09 million, a price-to-earnings ratio of -8.85 and a beta of 1.01. The firm's fifty day moving average is $17.78 and its 200-day moving average is $19.55.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.
Insider Activity at Tyra Biosciences
In other news, CEO Todd Harris sold 10,035 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $24.31, for a total value of $243,950.85. Following the completion of the sale, the chief executive officer now directly owns 1,467,338 shares of the company's stock, valued at $35,670,986.78. This represents a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Nina S. Kjellson sold 27,493 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now directly owns 458,506 shares of the company's stock, valued at $7,592,859.36. The trade was a 5.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,260 shares of company stock valued at $1,853,453 in the last three months. Corporate insiders own 15.40% of the company's stock.
Institutional Trading of Tyra Biosciences
A number of institutional investors and hedge funds have recently modified their holdings of TYRA. Bank of New York Mellon Corp increased its position in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock valued at $929,000 after purchasing an additional 14,352 shares during the last quarter. Rhumbline Advisers grew its position in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock valued at $377,000 after acquiring an additional 2,574 shares during the period. American Century Companies Inc. increased its stake in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock worth $2,723,000 after purchasing an additional 145,346 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth approximately $3,047,000. Finally, HighVista Strategies LLC purchased a new position in Tyra Biosciences in the second quarter valued at approximately $257,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
